![Cancers | Free Full-Text | Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study) Cancers | Free Full-Text | Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)](https://www.mdpi.com/cancers/cancers-11-00827/article_deploy/html/images/cancers-11-00827-g002.png)
Cancers | Free Full-Text | Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
![A hybrid design for dose‐finding oncology clinical trials - Liao - 2022 - International Journal of Cancer - Wiley Online Library A hybrid design for dose‐finding oncology clinical trials - Liao - 2022 - International Journal of Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/54bb178b-dd0f-4acd-92c3-212c06c4a96f/ijc34203-toc-0001-m.jpg)
A hybrid design for dose‐finding oncology clinical trials - Liao - 2022 - International Journal of Cancer - Wiley Online Library
![On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE) On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)](http://3.bp.blogspot.com/-wuebrZQwQk4/VLshyehJGII/AAAAAAAAAZY/DO9uJrwZ3l0/w1200-h630-p-k-no-nu/untitled.bmp)
On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)
![Frontiers | A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy Frontiers | A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy](https://www.frontiersin.org/files/Articles/616264/fonc-11-616264-HTML/image_m/fonc-11-616264-g001.jpg)
Frontiers | A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy
A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia | PLOS ONE
![Illustration of the chronic dose-limiting toxicity (DLT) concept. (*)... | Download Scientific Diagram Illustration of the chronic dose-limiting toxicity (DLT) concept. (*)... | Download Scientific Diagram](https://www.researchgate.net/publication/50891956/figure/fig2/AS:601789934096386@1520489309156/Illustration-of-the-chronic-dose-limiting-toxicity-DLT-concept-Coefficients.png)
Illustration of the chronic dose-limiting toxicity (DLT) concept. (*)... | Download Scientific Diagram
![Study design for dose-escalation cohorts and DLT rate (as calculated by... | Download Scientific Diagram Study design for dose-escalation cohorts and DLT rate (as calculated by... | Download Scientific Diagram](https://www.researchgate.net/publication/259253363/figure/fig1/AS:601583003893781@1520439973618/Study-design-for-dose-escalation-cohorts-and-DLT-rate-as-calculated-by-smoothed-toxicity.png)
Study design for dose-escalation cohorts and DLT rate (as calculated by... | Download Scientific Diagram
![Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study - ScienceDirect Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2451865416301053-gr3.jpg)
Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study - ScienceDirect
![Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. - Abstract - Europe PMC Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5047439/bin/nihms801570f1.jpg)
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. - Abstract - Europe PMC
![Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis](https://www.degruyter.com/document/doi/10.1515/pp-2018-0118/asset/graphic/j_pp-2018-0118_fig_001.jpg)
Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis
Biostatistical intepretation series II Clinical Trials Phase I - mitigating misinterpretation risk in dose escalation studies
![On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE) On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)](http://3.bp.blogspot.com/-wuebrZQwQk4/VLshyehJGII/AAAAAAAAAZY/DO9uJrwZ3l0/s1600/untitled.bmp)
On Biostatistics and Clinical Trials: Dose Limiting Toxicity (DLT) and Common Toxicity Criteria (CTC) / Common Terminology Criteria for Adverse Events (CTCAE)
![Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial - ScienceDirect Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2451865422000187-gr1.jpg)
Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial - ScienceDirect
![Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial - eClinicalMedicine Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial - eClinicalMedicine](https://www.thelancet.com/cms/attachment/596fab91-d995-4289-b14d-237f412f9483/gr1_lrg.jpg)
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial - eClinicalMedicine
![Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study. - Abstract - Europe PMC Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5898525/bin/gr2.jpg)
Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study. - Abstract - Europe PMC
![Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial | BMC Medical Research Methodology | Full Text Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12874-022-01584-y/MediaObjects/12874_2022_1584_Fig1_HTML.png)
Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial | BMC Medical Research Methodology | Full Text
![Principles of dose finding studies in cancer: a comparison of trial designs | Cancer Chemotherapy and Pharmacology Principles of dose finding studies in cancer: a comparison of trial designs | Cancer Chemotherapy and Pharmacology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00280-012-2059-8/MediaObjects/280_2012_2059_Fig2_HTML.gif)